New Two-Drug combo aims to shrink breast cancer before surgery
NCT ID NCT07396324
Summary
This study is testing whether adding two new immunotherapy drugs, called iparomlimab and tuvonralimab (together as QL1706), to standard chemotherapy before surgery can help shrink tumors in people with a common type of breast cancer. The goal is to see if this combination leads to no detectable cancer in the tissue removed during surgery, which is linked to better long-term outcomes. The trial will also closely monitor side effects in about 55 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, 200127, China
Conditions
Explore the condition pages connected to this study.